PHCCC

Research use only, not for human use.

PHCCC is a Group I metabotropic glutamate receptor antagonist and a positive allosteric modulator of mGluR4. It also is a potent to antagonism for mGluR2 and mGluR8.

PHCCC is a positive allosteric modulator of mGluR4. PHCCC exhibits proconvulsant action in three models of epileptic seizures in immature rats. PHCCC reduces proliferation and promotes differentiation of cerebellar granule cell neuroprecursors. PHCCC showed neuroprotection against betaAP- and NMDA-toxicity in mixed cultures of mouse cortical neurons. This neuroprotection was additive to that induced by the highly efficacious mGluR1 antagonist CPCCOEt and was blocked by MSOP, a group-III mGluR antagonist. Our data provide evidence for a novel pharmacological site on mGluR4, which may be used as a target-site for therapeutics.

PHCCC potentiated the effect of L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) in inhibiting transmission at the striatopallidal synapse.

PHCCC (75 nmol/2.5 μl; intracerebroventricular) produces an antiparkinsonian effect in a dopamine depletion akinesia model.

PHCCC

Endocrinology/Hormones

5-HT Receptor

mGluR1

Cancer

——

179068-02-1

294.31

C17H14N2O3

>98% (HPLC)

DMSO : ≥ 32 mg/mL; 108.73 mM

C12(C(/C(=N/O)/c3ccccc3O1)C2)C(=O)Nc1ccccc1

(E)-7-(hydroxyimino)-N-phenyl-7,7a-dihydrocyclopropa[b]chromene-1a(1H)-carboxamide

(-20℃)

With Ice Pack

≥ 2 years